Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$12.62 USD
+0.36 (2.89%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $12.73 +0.11 (0.87%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Intellia Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
NTLA 12.62 +0.36(2.89%)
Will NTLA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for NTLA
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus
Other News for NTLA
PLTR, KTOS, BLSH, NTLA: Cathie Wood Trims Stakes in Palantir and Kratos Defense, Doubles Down on Intellia
Cathie Wood Cuts Stake in Palantir Stock (PLTR) Ahead of Q3, Loads Up on Bullish (BLSH) and Intellia (NTLA)
Is NTLA preparing to trend lower? Lower Bollinger Band Walk shows up after rising 2.89%
DoorDash, Microsoft, Intellia, Upwork, Qorvo: Trending by Analysts
SA analyst upgrades/downgrades: AMZN, NVDA, CMG, NTLA